Opinion|Videos|September 30, 2024
Perspectives on Latest Therapies: Faricimab and Aflibercept 8mg
Author(s)Nikolas London, MD, FACS
Fact checked by: Nikolas London, MD, FACS
Dr. London discusses the implications of faricimab and aflibercept 8 mg in treating retinal diseases, highlighting their mechanisms, efficacy data, and potential to enhance patient outcomes in conditions like wet age-related macular degeneration.
Advertisement
Advertisement
Related to this article
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA requires NAION warning across the GLP-1 receptor agonist class
2
Longer anti-VEGF intervals in AMD, BRVO, and DME: 3 clinical cases
3
Tenpoint Therapeutics opens telehealth access to Yuvezzi for adults with presbyopia
4
The interplay between cardiac disease and the eye
5